AbbVie M14-064 for Metastatic Colorectal Cancer - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find if the study drug called ABT-165 given in combination with
the standard of care treatment, FOLFIRI, will work better than an approved standard treatment
combination for metastatic colorectal cancer.
Who Can Participate in the Study?
- Have colorectal cancer
- Have received prior therapy that included a fluoropyrimidine, oxaliplatin, and bevacizumab
What is Involved?
If you choose to join this study you will:
- Be randomized (like the flip of a coin) to either get:
-- The study drug ABT-165 plus FOLFIRI OR Bevacizumab plus FOLFIRI through your vein
--- Infusions will be given on Day 1 of each 14-day cycle
- Have tests, exams, and procedures that are part of your standard care and for study purposes